Coegin Pharma
Coegin Pharma is a Swedish biotechnology company developing cutting-edge innovations for hair growth and skin pigmentation. They focus on proprietary peptides with planned product launches in 2025 and 2026, respectively. The company aims to lead the future of solutions for hair and skin longevity, leveraging collaborations with leading universities and a strategic focus on the global longevity market.
Industries
Nr. of Employees
small (1-50)
Coegin Pharma
c/o Medicon Village, 223 81 Lund, Sweden
Products
Topical peptide product for hair growth (planned launch end 2025)
A peptide-based topical product intended to address hair growth; development and launch planned by end of 2025.
Topical peptide product for skin pigmentation (planned launch 2026)
A peptide-based topical product intended to modulate natural skin pigmentation; development and launch planned in 2026.
Topical peptide product for hair growth (planned launch end 2025)
A peptide-based topical product intended to address hair growth; development and launch planned by end of 2025.
Topical peptide product for skin pigmentation (planned launch 2026)
A peptide-based topical product intended to modulate natural skin pigmentation; development and launch planned in 2026.
Services
Collaborative translational research partnerships with universities to support discovery and validation of peptide candidates.
Engagement with potential licensing or co-development partners to advance clinical assets and execute commercialization or exit strategies within a hub-and-spoke portfolio structure.
Collaborative translational research partnerships with universities to support discovery and validation of peptide candidates.
Engagement with potential licensing or co-development partners to advance clinical assets and execute commercialization or exit strategies within a hub-and-spoke portfolio structure.
Expertise Areas
- Cosmetic peptide development
- Hair growth therapeutics development
- Skin pigmentation therapeutics development
- Clinical trial management for dermatology indications
Key Technologies
- Peptide-based therapeutics
- Biomarker strategies for dermatology
- Decentralized clinical trial methodologies
- Small-molecule target inhibition (enzyme targets)
News & Updates
Coegin Pharma offentliggör årsredovisning för 2022
Coegin Pharma AB publicly announces the annual report for 2022, highlighting their strengthened pipeline and ongoing business development efforts.
Coegin Pharma accelererar sina affärsutvecklingsaktiviteter och anlitar BioPharma Connections
The company accelerates its business development activities by engaging BioPharma Connections as its business development advisor to identify and secure potential partners.
BioStock publicerar intervju med verkställande direktör Tore Duvold avseende den föreslagna fusionen med Follicum
An interview with CEO Tore Duvold discussing the proposed merger with Follicum, emphasizing the company's focus on developing small molecule-based cancer treatments targeting cPLA2α.
Coegin Pharma offentliggör årsredovisning för 2022
Coegin Pharma AB publicly announces the annual report for 2022, highlighting their strengthened pipeline and ongoing business development efforts.
Coegin Pharma accelererar sina affärsutvecklingsaktiviteter och anlitar BioPharma Connections
The company accelerates its business development activities by engaging BioPharma Connections as its business development advisor to identify and secure potential partners.
BioStock publicerar intervju med verkställande direktör Tore Duvold avseende den föreslagna fusionen med Follicum
An interview with CEO Tore Duvold discussing the proposed merger with Follicum, emphasizing the company's focus on developing small molecule-based cancer treatments targeting cPLA2α.